A Safe, Orally Administered Agent for Dengue [ 2017 - ]

Research Grant

Researchers: Prof David Jans (Principal investigator) ,  Dr Geoffrey Dow ,  Dr Jenny Low ,  Dr Kylie Wagstaff ,  Prof Christopher Porter
View all 7 related researchers

Brief description Dengue virus is the most important mosquito-borne viral disease, with 2/3 of the world's population at risk. There is currently no treatment available for dengue. Our proposal aims to progress a safe and effective new treatment (4-HPR) against Dengue towards the clinic, generating all the required pharmacokinetic and pre-clinical animal data necessary to progress to a future clinical trial in humans. We will also investigate the use of 4-HPR as a dengue preventative.

Funding Amount $857,659.00

Funding Scheme Development Grants

Notes Development Grant